Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer

Significant improvement in targeted therapy for colorectal cancer (CRC) has occurred over the past few decades since the approval of the EGFR inhibitor cetuximab. However, cetuximab is used only for patients possessing the wild-type oncogene KRAS, NRAS, and BRAF, and even most of these eventually ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yoon Sun, kim, Joseph, Ryu, Yea Seong, moon, Jai-Hee, shin, Yu Jin, kim, Jeong Hee, hong, Seung-Woo, jung, Soo-A, lee, Seul, kim, Seung-Mi, lee, Dae Hee, kim, Do Yeon, yun, Hyeseon, you, Ji-Eun, yoon, Dong Il, kim, Chul Hee, koh, Dong-In, jin, Dong-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461515/
https://www.ncbi.nlm.nih.gov/pubmed/37621144
http://dx.doi.org/10.1080/15384047.2023.2246208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461515/
https://www.ncbi.nlm.nih.gov/pubmed/37621144
http://dx.doi.org/10.1080/15384047.2023.2246208

Ejemplares similares